M. Bilal Abid, Medical Director, Blood and Marrow Transplantation and Cellular Therapy Program at Texas Tech University Health Sciences Center, shared a post on LinkedIn:
“Publication alert
Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings
The off-the-shelf availability and manageable immune-mediated toxicities associated with BsAbs make them ideal for widespread utilization. Adoption of BsAb products in outpatient and community settings will allow greater and more homogeneous access and thus improve patient outcomes.
In this review, we discuss the unique toxicities associated with BsAbs currently approved by the U.S. Food and Drug Administration and provide a disease-agnostic framework for safe community administration of BsAb therapy. With academic, community, and industrial partnerships, broader deployment of BsAbs could be streamlined.
Education, provision of in-services, leveraging protocols and experiences, and development of templates and guidelines will make this transition smoother and allow every patient in need of BsAbs to receive timely access to these survival-prolonging therapies.
Work co-led by 2 star hem/onc fellows and oncologists in the making (they were also very patient with multiple revisions and peer review that took nearly 2 years).”
Title: Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings
Authors: Amrit S. Gonugunta, Asad Haider, Virginia Mohlere, Mahmoud Aljurf, Shahrukh Hashmi, Muhammad Bilal Abid
Other articles on OncoDaily.
